Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Cellectar Biosciences, Inc. has a significant shareholder group led by Bleichroeder entities and Andrew Gundlach. Bleichroeder LP, an investment adviser registered under the Investment Advisers Act of 1940, is deemed the beneficial owner of 808,300 common shares, representing 9.99% of Cellectar’s common stock believed to be outstanding. Bleichroeder Holdings LLC and Andrew Gundlach are also listed as reporting persons, each with sole voting and sole dispositive power over 808,300 shares, and no shared voting or dispositive power. The shares are held for various advisory clients of Bleichroeder, and those clients have the right to receive, and ultimately direct, the receipt of dividends and sale proceeds from these securities.
Key Figures
Beneficially owned shares:808,300 sharesOwnership percentage:9.99%Sole voting power:808,300 shares+2 more
5 metrics
Beneficially owned shares808,300 sharesCommon shares of Cellectar Biosciences deemed beneficially owned by Bleichroeder LP and affiliates
Ownership percentage9.99%Percentage of Cellectar common stock believed to be outstanding
Sole voting power808,300 sharesShares over which each reporting person has sole power to vote
Sole dispositive power808,300 sharesShares over which each reporting person has sole power to dispose
CUSIP15117F880CUSIP number for Cellectar Biosciences, Inc. common shares
Key Terms
beneficial owner, sole voting power, sole dispositive power, Investment Advisers Act of 1940, +1 more
5 terms
beneficial ownerfinancial
"is deemed to be the beneficial owner of 808,300 shares, or 9.99% of the common stock"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
sole voting powerfinancial
"5 | Sole Voting Power 808,300.00 6 | Shared Voting Power 0.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive powerfinancial
"7 | Sole Dispositive Power 808,300.00 8 | Shared Dispositive Power 0.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Investment Advisers Act of 1940regulatory
"an investment adviser registered under Section 203 of the Investment Advisers Act of 1940"
A U.S. federal law that sets rules for people and firms who give investment advice, requiring them to register with regulators, be honest about conflicts, keep records, and follow basic standards of care. It matters to investors because those rules act like licensing and consumer protections — similar to having safety standards for a mechanic — helping ensure advisers act in clients’ financial interests and reducing the risk of fraud or misuse of funds.
percent of classfinancial
"(b) | Percent of class: See cover page."
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many Cellectar Biosciences (CLRB) shares are reported as beneficially owned?
The reporting group is deemed to beneficially own 808,300 Cellectar common shares. These shares are held in client accounts advised by Bleichroeder LP, which reports investment and voting authority over this position.
What percentage of Cellectar Biosciences (CLRB) does Bleichroeder LP report owning?
Bleichroeder LP reports beneficial ownership of 9.99% of Cellectar’s common stock believed to be outstanding. This percentage reflects shares managed for various advisory clients rather than proprietary holdings.
Who are the reporting persons in this Cellectar (CLRB) ownership report?
The reporting persons are Bleichroeder Holdings LLC, Bleichroeder LP, and Andrew Gundlach. Each is listed with beneficial ownership over the same 808,300 common shares of Cellectar Biosciences, Inc.
What voting power over Cellectar (CLRB) shares do the reporting persons have?
Each reporting person has sole voting power over 808,300 shares and no shared voting power. They also have sole dispositive power over the same number of Cellectar common shares.
Who ultimately benefits from the Cellectar (CLRB) shares managed by Bleichroeder LP?
Clients of Bleichroeder LP ultimately benefit from the 808,300 Cellectar shares. These clients have the right to receive dividends and direct the receipt of proceeds from any sale of the securities.
Where are the reporting persons for this Cellectar (CLRB) stake based?
The principal business office of the reporting persons is at 1345 Avenue of the Americas, 47th Floor, New York, NY 10105, while Cellectar’s principal executive offices are in Park, NJ 07932.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Cellectar Biosciences, Inc.
(Name of Issuer)
Common Shares
(Title of Class of Securities)
15117F880
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
15117F880
1
Names of Reporting Persons
Bleichroeder LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
808,300.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
808,300.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
808,300.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP Number(s):
15117F880
1
Names of Reporting Persons
Bleichroeder Holdings LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
808,300.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
808,300.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
808,300.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP Number(s):
15117F880
1
Names of Reporting Persons
Andrew Gundlach
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
808,300.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
808,300.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
808,300.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Cellectar Biosciences, Inc.
(b)
Address of issuer's principal executive offices:
100 CAMPUS DRIVE, FLORHAM PARK, NJ 07932
Item 2.
(a)
Name of person filing:
Bleichroeder Holdings LLC
Bleichroeder LP
Andrew Gundlach
(b)
Address or principal business office or, if none, residence:
1345 Avenue of the Americas, 47th Floor
New York, NY 10105
(c)
Citizenship:
Bleichroeder Holdings LLC and Bleichroeder LP: Delaware, USA
Andrew Gundlach: United States
(d)
Title of class of securities:
Common Shares
(e)
CUSIP Number(s):
15117F880
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See cover page.
(b)
Percent of class:
See cover page.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See cover page.
(ii) Shared power to vote or to direct the vote:
See cover page.
(iii) Sole power to dispose or to direct the disposition of:
See cover page.
(iv) Shared power to dispose or to direct the disposition of:
See cover page.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Bleichroeder LP ("Bleichroeder"), an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 808,300 shares, or 9.99% of the common stock believed to be outstanding as a result of acting as investment adviser to various clients. Clients of Bleichroeder have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Exhibit 99.1
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Bleichroeder LP
Signature:
Andrew Gundlach
Name/Title:
President and CEO
Date:
08/14/2026
Bleichroeder Holdings LLC
Signature:
Andrew Gundlach
Name/Title:
President and CEO
Date:
08/14/2026
Andrew Gundlach
Signature:
Andrew Gundlach
Name/Title:
President and CEO
Date:
08/14/2026
Exhibit Information
Exhibit 99.1 AGREEMENT OF THE REPORTING PERSONS
Exhibit 99.2 Subsidiary Information
